Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Retapamulin as a Topical Decolonizing Agent for Mupirocin Resistant Methicillin Resistant Staphylococcus Aureus (MRSA)

NCT03304873 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT03304873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03304873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Retapamulin as a Topical Decolonizing Agent for Mupirocin Resistant Methicillin Resistant Staphylococcus Aureus (MRSA)
Lead sponsor
NYU Langone Health
Phase
Phase 3
Overall status
Completed
Start date
December 1, 2017
Completion date
March 18, 2019
Enrollment
47 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mrsa